Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. 3D Medicines's annualized net income for the quarter that ended in Dec. 2025 was HK$-194.8 Mil. 3D Medicines's average shareholder tangible equity for the quarter that ended in Dec. 2025 was HK$720.4 Mil. Therefore, 3D Medicines's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -27.04%.
The historical rank and industry rank for 3D Medicines's Return-on-Tangible-Equity or its related term are showing as below:
HKSE:01244'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -55.29 Med: -26.22 Max: -20.96
Current: -25.69
During the past 6 years, 3D Medicines's highest Return-on-Tangible-Equity was -20.96%. The lowest was -55.29%. And the median was -26.22%.
HKSE:01244's Return-on-Tangible-Equity is ranked better than 60.68% of 1198
companies
in the Biotechnology industry
Industry Median: -42.66
vs HKSE:01244: -25.69
3D Medicines (HKSE:01244) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
3D Medicines Return-on-Tangible-Equity Related Terms
3D Medicines Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for 3D Medicines's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01244 vs VRTX, REGN, RVMD: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, 3D Medicines's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3D Medicines Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3D Medicines's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where 3D Medicines's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -27.04% mean?
3D Medicines (HKSE:01244) has a Return-on-Tangible-Equity of -27.04% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on 3D Medicines and its competitors. According to the industry distribution chart, 3D Medicines ranks #471 out of 1198 companies in the Biotechnology industry, placing it in the top 39.3%.
Is 3D Medicines' Return-on-Tangible-Equity too high?
3D Medicines' current Return-on-Tangible-Equity is -27.04%. Based on the distribution chart, 3D Medicines ranks #471 out of 1198 companies in the Biotechnology industry, which is above the industry midpoint. Overall, 3D Medicines has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 3D Medicines' Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3D Medicines ranks #471 out of 1198 companies for Return-on-Tangible-Equity. This puts 3D Medicines in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on 3D Medicines and its competitors. 3D Medicines's current Return-on-Tangible-Equity is -27.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3D Medicines stock overvalued right now?
Based on GuruFocus' analysis, 3D Medicines (HKSE:01244) is currently considered Possible Value Trap. The stock's GF Value™ is HK$3.15, compared to a current price of HK$2.02 — trading 36% below its estimated fair value. The current Return-on-Tangible-Equity is -27.04%. 3D Medicines' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For 3D Medicines (HKSE:01244), the current Return-on-Tangible-Equity is -27.04% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3D Medicines (HKSE:01244) Overvalued in 2026?
Based on GuruFocus' analysis, 3D Medicines stock appears to be undervalued.
The current stock price of HK$2.02 is trading 36% below its estimated GF Value™ of HK$3.15.
GuruFocus considers 3D Medicines to be Possible Value Trap.
Key valuation signals for HKSE:01244:
Return-on-Tangible-Equity: -27.04%
GF Value™: HK$3.15 vs. price of HK$2.02 (36% below fair value)
No single metric tells the full story. See the HKSE:01244 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3D Medicines Inc is an investment holding company. The company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products.It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China. Its commercialized product is Envita.
49GF Score
Get the complete analysis for HKSE:01244
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01244 has been successfully added to your 
